Sector News

Coloplast picks up voice box maker Atos Medical in €2B deal

November 14, 2021
Life sciences

Danish medtech Coloplast has agreed to acquire voice box maker Atos Medical for 2.15 billion euros, or about $2.49 billion.

That deal represents a healthy return for Atos’ private equity owner, Paris-based PAI Partners, which bought the Swedish company back in 2016 for about 850 million euros. Coloplast describes Atos as an international market leader in the field of laryngectomy and a potential route to a new chronic care business.

Founded in 1986, Atos has been producing prosthetic voice boxes for over 30 years, designed for patients who have had their larynx surgically removed due to cancer or other conditions.

The company introduced an updated version of its Provox device in 2014, which helped users to speak hands-free. Since then, it has launched a smartphone app for voice rehabilitation exercises as well as devices designed for pediatric cases.

After the closure of the deal, which is slated for early 2022, Coloplast plans to run Atos as a separate strategic unit and brand; however, the company will operate on a shared business infrastructure that also supports Coloplast’s offerings in urology, continence and wound care, according to a statement.

Atos recently completed an acquisition of its own—nabbing three companies in one—to diversify into products for patients who have received a tube placed in their windpipe.

A deal was finalized last month for the German tracheostomy group TRACOE medical, which also oversees the Netherlands-based airway management developer MC Europe, and Kapitex, a U.K. manufacturer and distributor of medical devices for people with trouble swallowing.

“I am convinced that combining our companies will strengthen our ability to fast track the journey towards becoming a full range global player in the tracheostomy segment through a combined hospital and direct-to-consumer model and with a strong production footprint in Sweden and Germany,” Atos CEO Britt Meelby Jensen said in a statement when the deals closed Oct. 1.

The sale to Coloplast follows a report from Reuters this past summer that Atos Medical was gearing up to go public, potentially aiming for a 2 billion euro valuation.

“It has been very rewarding to be able to support Atos Medical’s growth in the last few years, with the company more than doubling in size and transforming into a true direct-to-consumer medtech company,” said Andreas Kumeth, partner at PAI. “We are also proud to have played a role in helping Atos Medical establish further specialities and become a more diversified ENT specialist.”

by Conor Hale

Source: fiercebiotech.com

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend